Stock Events

Stock Events

Nkarta 

$2.92
47
+$0.13+4.66% 19:57 Today
-$0.02-0.68%22:25After hours

Statistics

Day High
2.93
Day Low
2.87
52W High
3.72
52W Low
1.7
Volume
21,246
Avg. Volume
-
Mkt Cap
209.14M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.54
-0.46
-0.37
-0.29
Expected EPS
-0.395
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-104.08MNet Income

Analyst Ratings

11.75Average Price Target
The highest estimate is 14.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NKTX. It's not an investment recommendation.
Microsoft
13
MSFT
Amazon
12
AMZN
NVIDIA
11
NVDA
Tesla
10
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies for cancer and immune disorders, directly competing with Nkarta's NK cell therapy approach.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing and CAR-T cell therapies, which are in direct competition with Nkarta's work on engineering NK cells for cancer treatment.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics focuses on allogeneic CAR-T cell therapies, a direct competitor to Nkarta's allogeneic NK cell therapy approach.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR-T cell therapies, competing in the broader cell therapy market against Nkarta.
Novartis
NVS
Mkt Cap292.35B
Novartis is a major player in the CAR-T cell therapy space with Kymriah, competing in the advanced therapy medicinal products (ATMPs) market, including NK cell therapies.
Precigen
PGEN
Mkt Cap2.49B
Precigen is a biotechnology company that develops CAR-T and TCR therapies, competing in the cell therapy market against companies like Nkarta.

About

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Show more...
CEO
Paul J. Hastings
Employees
106
Country
United States
ISIN
US65487U1088

Listings

BOATS
BOATS
NKTX.BOATS
XNAS
US
NKTX

0 Comments

Share your thoughts

FAQ

What is Nkarta stock price today?▼
The current price of NKTX is $2.92 USD — it has increased by +4.66% in the past 24 hours. Watch Nkarta stock price performance more closely on the chart.
What is Nkarta stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Nkarta stocks are traded under the ticker NKTX.
Is Nkarta stock price growing?▼
NKTX stock has risen by +5.8% compared to the previous week, the month change is a +29.2% rise, over the last year Nkarta has showed a +37.09% increase.
What is Nkarta market cap?▼
Today Nkarta has the market capitalization of 209.14M
When is the next Nkarta earnings date?▼
Nkarta is going to release the next earnings report on November 11, 2026.
What were Nkarta earnings last quarter?▼
NKTX earnings for the last quarter are -0.54 USD per share, whereas the estimation was -0.36 USD resulting in a -49.87% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nkarta revenue for the last year?▼
Nkarta revenue for the last year amounts to 0 USD.
What is Nkarta net income for the last year?▼
NKTX net income for the last year is -104.08M USD.
How many employees does Nkarta have?▼
As of September 04, 2026, the company has 106 employees.
In which sector is Nkarta located?▼
Nkarta operates in the Health & Wellness sector.
When did Nkarta complete a stock split?▼
Nkarta has not had any recent stock splits.
Where is Nkarta headquartered?▼
Nkarta is headquartered in SOUTH SAN FRANCISCO, United States.